MARYAM OLADEJO: Open Payments
NPI 1770288102 · STAFFORD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,969 in 112 payments from 11 companies in 2025. Trend: 2023 $948 · 2024 $1,341 · 2025 $2,969
Food & beverage: $2,969
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $709 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $560 |
| Alkermes, Inc. | 19 | $447 |
| Neurocrine BioSciences, Inc. | 8 | $358 |
| E.R. Squibb & Sons, L.L.C. | 14 | $308 |
| Janssen Pharmaceuticals, Inc | 15 | $266 |
| Otsuka America Pharmaceutical, Inc. | 7 | $210 |
| Vanda Pharmaceuticals Inc. | 4 | $65 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
Products named: CAPLYTA, UZEDY, COBENFY, AUSTEDO XR, INVEGA SUSTENNA, ARISTADA, INGREZZA, LYBALVI.
Industry payments across TX — which companies pay providers there.
